683 Capital Management’s Cabaletta Bio CABA Stock Holding History

683 Capital Management’s Portfolio CABA Stock Details CABA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-225,000	Closed	-$605K	–	168
2026 Q1	$605K	Sell	225,000 -163,562	-42%	-$454K	0.03%	172
2025 Q4	$851K	Buy	+388,562	New	+$963K	0.04%	157
2023 Q2	–	Sell	-17,000	Closed	-$141K	–	186
2023 Q1	$141K	Sell	17,000 -9,963	-37%	-$93.2K	0.01%	212
2022 Q4	$249K	Buy	+26,963	New	+$98.2K	0.02%	140
2022 Q1	–	Sell	-36,118	Closed	-$137K	–	360
2021 Q4	$137K	Buy	+36,118	New	+$385K	0.01%	293

Other funds holding CABA

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

683 Capital Management's CABA Position: Q2 2026 in Review

683 Capital Management sold out of Cabaletta Bio (CABA) in Q2 2026, closing a stake of 225,000 shares — an estimated $605K sold.

683 Capital Management first reported a position in CABA in Q4 2021 and held it in 5 quarters. The position peaked at $851K in Q4 2025. 140 funds tracked by Wall St. Rank hold CABA as of Q2 2026.

683 Capital Management reported no remaining Cabaletta Bio position as of Q2 2026 after selling out during the quarter.
683 Capital Management sold 225,000 Cabaletta Bio shares in Q2 2026, an estimated $605K.
683 Capital Management first reported a position in Cabaletta Bio in Q4 2021 and held it in 5 quarters.
683 Capital Management's Cabaletta Bio position peaked at $851K in Q4 2025.
140 funds tracked by Wall St. Rank held Cabaletta Bio as of Q2 2026.

Based on 683 Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.